PTC Therapeutics Targets $500 Million Debt Refinancing

The Warren, New Jersey-based firm will offer the notes to qualified institutional buyers, with an option for purchasers to acquire an additional $50 million in debt. These senior unsecured obligations will accrue interest semiannually, with conversion terms—whether in cash, shares, or a mix—to be finalized at the time of pricing.

Management intends to direct the proceeds toward repurchasing 1.5% convertible senior notes maturing in 2026. Because many holders of the 2026 notes utilize arbitrage strategies involving short positions in PTC stock, the company anticipates that concurrent repurchases may trigger shifts in market volatility. These hedging activities, including the unwinding of derivatives, could influence the stock price and, by extension, the effective conversion price of the new notes.